

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-873-I (500.011))

In the Application of:

Thompson et al.

Serial No.: 10/715,285

Filing Date: November 17, 2003

For: Nucleic Acid Molecules with Novel
Chemical Compositions Capable of
Modulating Gene Expression

Examiner: TBD

Group Art Unit: TBD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:


- ☒ Information Disclosure Statement;
- ☒ Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/715,285 (Total 1 foreign patent and 15 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on MARCH 23 2004.

By :


Christopher P. Singer
Reg. No. 48,701



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-873-I (500.011))**

In the Application of:)	
)	
Thompson et al.)	
)	Examiner: TBD
Serial No.: 10/715,285)	
)	Group Art Unit: TBD
Filing Date: November 17, 2003)	
)	
For: Nucleic Acid Molecules with Novel)	
Chemical Compositions Capable of)	
Modulating Gene Expression)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. This application is a continuation of US Serial No. 09/866,316, filed May 25, 2001, which is a continuation-in-part of US Serial No. 09/103,636, filed June 23, 1998, which claims priority to US Serial No. 60/082,404, filed April 20, 1998, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 CFR §1.98(d), those references marked with an "*" have been previously cited and submitted to the Patent and Trademark Office with the prior applications and additional references are enclosed herein. All references cited are also listed in the PTO-1449 form enclosed herewith.

The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the

national stage under 35 USC § 371 after June 30, 2003. In accordance with this waiver, cited U.S. patents and U.S. patent application publications are not enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

U. S. PATENT APPLICATION DOCUMENTS

- * Thomspen et al., U.S. Patent Application No. 09/103,636, filed June 23, 1998
- * Thompson et al., U.S. Patent Application No. 09/886,316, filed May 25, 2001
- * Thompson et al., U.S. Patent Application No. 60/082,404, filed April 20, 1998
- * Hartmann et al., U.S. Patent Application No. 60/101,074, filed September 21, 1998

U.S. PATENTS

- * Cech et al., U.S. Patent No. 4,987,071, issued January 22, 1991
- * Ohtsuka et al., U.S. Patent No. 5,013,830, issued May 7, 1991
- * Rossi et al., U.S. Patent No. 5,144,019, issued September 1, 1992
- * Cohen et al., U.S. Patent No. 5,264,423, issued November 23, 1993
- * Inouye et al., U.S. Patent No. 5,272,065, issued December 21, 1993
- * Cohen et al., U.S. Patent No. 5,276,019, issued January 4, 1994
- * Cohen et al., U.S. Patent No. 5,286,717, issued February 15, 1994
- * Sproat et al., U.S. Patent No. 5,334,711, issued August 2, 1994
- * Walder et al., U.S. Patent No. 5,491,133, issued February 13, 1996
- * Draper et al., U.S. Patent No. 5,496,698, issued March 5, 1996
- * McSwiggen, U.S. Patent No. 5,525,468, issued June 11, 1996

- * Monia et al., U.S. Patent No. 5,576,208, issued November 19, 1996
- * Chu et al., U.S. Patent No. 5,587,362, issued December 24, 1996
- * Cook et al., U.S. Patent No. 5,623,065, issued April 22, 1997
- * Noonberg et al., U.S. Patent No. 5,624,803, issued April 29, 1997
- * Been et al., U.S. Patent No. 5,625,047, issued April 29, 1997
- * Usman et al., U.S. Patent No. 5,627,053, issued May 6, 1997
- * Chowrira et al., U.S. Patent No. 5,631,359, issued May 20, 1997
- * Long et al., U.S. Patent No. 5,633,133, issued May 27, 1997
- * Usman et al., U.S. Patent No. 5,652,094, issued July 29, 1997
- * Metelev et al., U.S. Patent No. 5,652,356, issued July 29, 1997
- * Agrawal, U.S. Patent No. 5,652,356, issued July 29, 1997
- * Okamura et al., U.S. Patent No. 5,678,731, issued October 21, 1997
- * Beigelman et al., U.S. Patent No. 5,716,824, issued February 10, 1998
- * Arrow et al., U.S. Patent No. 5,849,902, issued December 15, 1998
- * Tullis, U.S. Patent No. 5,919,619, issued July 6, 1999
- * Arrow et al., U.S. Patent No. 5,989,912, issued November 23, 1999
- * Matulic-Adamic et al., U.S. Patent No. 5,998,203, issued December 7, 1999
- * Brennan, U.S. Patent No. 6,001,311, issued December 12, 2000
- * Crooke et al., U.S. Patent No. 6,001,653, issued December 4, 2000
- * Eckstein et al., U.S. Patent No. 6,127,173, issued October 3, 2000
- * Usman et al., U.S. Patent No. 6,159,714, issued December 14, 1999
- * Seliger et al., U.S. Patent No. 6,420,546, issued July 16, 2002

FOREIGN PATENT DOCUMENTS

- * Hampel et al., European Patent Application No. 0360257 A2, filed March 28, 1990
- * Arnold et al., International Patent Application No. WO 89/02439, filed March 23, 1989
- * Rossi et al., International Patent Application No. WO 91/03162, filed March 21, 1991
- * Eckstein et al., International Patent Application No. WO 92/07065, filed April 30, 1992
- * Usman et al., International Patent Application No. WO 93/15187, filed August 5, 1993
- * Draper et al., International Patent Application No. WO 93/23569, filed November 25, 1993

- * Sullivan et al., International Patent Application No. WO 94/02595, filed February 3, 1994
- 1. Usman et al., International Patent Application No. WO 95/06731, filed March 9, 1995
- * Dudycz, International Patent Application No. WO 95/11910, filed May 4, 1995
- * Ansell et al., International Patent Application No. WO 96/10390, filed April 11, 1996
- * Choi et al., International Patent Application No. WO 96/10391, filed April 11, 1996
- * Holland et al., International Patent Application No. WO 96/10392, filed April 11, 1996
- * Joyce et al., International Patent Application No. WO 96/17086, filed June 6, 1996
- * Beigelman et al., International Patent Application No. WO 96/18736, filed June 20, 1996
- * Collins, International Patent Application No. WO 96/19577, filed June 27, 1996
- * Wincott et al., International Patent Application No. WO 97/26270, filed July 24, 1997
- * Woolf, International Patent Application No. WO 98/13526, filed April 2, 1998
- * Ludwig et al., International Patent Application No. WO 98/58058, filed December 23, 1998
- * Klimuk et al., International Patent Application No. WO 99/04819, filed February 4, 1999
- * Beigelman et al., International Patent Application No. WO 99/05094, filed July 22, 1998
- * Eckstein et al., International Patent Application No. WO 99/16871, filed April 8, 1999
- * Thompson et al., International Patent Application No. WO 99/54459, filed October 28, 1999
- * Beigelman et al., International Patent Application No. WO 99/55857, filed April 28, 1999

OTHER DOCUMENTS

- * Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," Science 271:1410-1413 (1996)
- * Agrawal et al., "Site-specific excision from RNA by Rnase H and mixed-phosphate-backbone oligodeoxynucleotides," Proc. Nat. Acad. Sci. USA 87:1401-1405 (1990)
- 2. Agrawal et al., "Antisense therapeutics: is it as simple as complementary base recognition?" *Molecular Medicine Today*, 6:72-81 (2000)
- * Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," *Trends in Cell Biology* 2:139-144 (1992)
- * Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a *retro-inverso* delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," Nucleic Acids Research 26:4910-4916 (1998)
- * Altmann et al., "Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals," Chimia 50:168-176 (1996)
- * Ashley, "Modeling, Synthesis, and Hybridization Properties of (L)-Ribonucleic Acid," J. Am.

Chem. Soc. 114:9731-9736 (1992)

- * Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," Biochemistry 34:6504-6512 (1995)
- * Bartel and Szostak, "Isolation of New Ribozymes From a Large Pool of Random Sequences," Science 261:1411-1418 (1993)
- * Beaucage et al., "The functionalization of oligonucleotides via phosphoramidite derivatives," Tetrahedron 49:1925-1963 (1993)
- * Beaudry et al., "Directed Evolution of an RNA Enzyme," Science 257:635-641 (1992)
- * Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," J. Biol. Chem. 270:25702-25708 (1995)
- * Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," Nucleosides & Nucleotides 16:951-954 (1997)
- * Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid-Phase Synthesis," Bioconjugate Chem. 8:204-212 (1997)
- 3. Bennett et al., "Pharmacology of Antisense Therapeutic Agents," *Methods in Molecular Medicine*, 13-46 (1996)
- * Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," EBMO J. 12:2567-2574 (1993)
- * Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," Genes & Development 6:129-134 (1992)
- * Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the *Tetrahymena* Ribozyme," Biochemistry 35:648-658 (1996)
- * Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," *Journal of Pharmaceutical Sciences* 87:1308-1315 (1998)
- * Boado, "Antisense drug delivery through the blood-brain barrier," *Advanced Drug Delivery Reviews* 15:73-107 (1995)
- * Borrás et al., "Estradiol-induced Down-regulation of Estrogen Receptor. Effect of Various Modulators of Protein Synthesis and Expression," J. Steroid Biochem. Molec. Biol. 48:325-336 (1994)
- * Borrás et al., "Estrogenic and Antiestrogenic Regulation of the Half-life of Covalently Labeled Estrogen Receptor in MCF-7 Breast Cancer Cells," J. Steroid Biochem. Molec. Biol. 57:203-213 (1996)
- 4. Branch, "A good antisense molecule is hard to find," TIBS 23:45-50 (1998)
- * Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," TIBTECH 12:268-275 (1994)
- * Breaker et al., "A DNA enzyme with Mg²⁺-dependent RNA phosphoesterase activity," Chemistry & Biology 2(10):655-660 (1995)

- * Breaker, "Are engineered proteins getting competition from RNA?" Current Opinion in Biotechnology 7:442-448 (1996)
- * Breaker, "Catalytic DNA: in training and seeking employment," *Nature Biotechnology* 17:422-423 (1999)
- * Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," *Biotechnology and Bioengineering (Combinatorial Chemistry)* 61:33-45 (1998)
- * Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no mistakenly listed as 6)
- * Burke et al., "Structural Analysis and Modifications of the Hairpin Ribozyme," Nucleic Acids and Molecular Biology, edited by Eckstein and Lilley, Springer-Verlag Berlin Heidelberg, 10:129-143 (1996)
- * Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes," *Bioorganic & Medicinal Chemistry* 5:1999-2010 (1997)
- * Cao and Matteucci, "Preparation, Characterization and Binding Properties of an Oligodeoxynucleotide Containing the 3'-Ribothioformacetal Phosphate Analog," Bioorganic & Medicinal Chemistry Letters 4:807-810 (1994)
- * Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," Methods in Enzymology 211:3-19 (1992)
- * Cech et al., "Representation of the secondary and tertiary structure of group I introns," structural biology 1:273-280 (1994)
- * Cech, "Ribozymes and Their Medical Implications," *JAMA* 260:3030-3034 (1988)
- * Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," Nucleic Acids Research 23(20):4092-4096 (1995)
- * Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," Nucleic Acids Research 20:4581-4589 (1992)
- * Chowrira et al., "*In Vitro* and *in Vivo* Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," J. Biol. Chem. 269:25856-25864 (1994)
- * Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," Nature 354:320-322 (1991)
- * Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," J. Med. Chem. 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
- * Christoffersen, "Translating genomics information into therapeutics: A Key Role for Oligonucleotides," Nature Biotechnology 15:483-484 (1997) (Christofferson)
- * Christofferson et al., "Application of computational technologies to ribozyme biotechnology products," Journal of Molecular Structure (Theochem) 311:273-284 (1994) (Christoffersen)
- * Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," J. Am. Chem. Soc.

113:6324-6326 (1991)

5. Cook et al., "Ch. 9 - Medicinal Chemistry Strategies for Antisense Research," Antisense Research and Applications, CRC Press, Inc., pp. 140-181 (1993)
 - * Cook et al., "The Use of Antisense Oligonucleotides to Establish Autocrine Angiotensin Growth Effects in Human Neuroblastoma and Mesangial Cells," Antisense Research and Development 2:199-210 (1992)
 - * Cosstick et al., "Synthesis and properties of dithymidine phosphate analogues containing 3'-thiothymidine," Nucleic Acids. Research 18:829-835 (1990)
 - * Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," Trends In Genetics 12:510-515 (1996)
 - * Crooke et al., "Kinetic characteristics of *Escherichia coli* RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes," Biochem. J. 312:599-608 (1995)
6. Crooke et al., "Progress in the development and patenting of antisense drug discovery technology," Exp. Opin. Ther. Patents, 6, 855 (1996)
 - * Crooke, "Progress in Antisense Therapeutics," Medicinal Research Reviews 16:319-344 (1996)
 - * Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," Advances in Pharmacology 40:1-49 (1997)
 - * Crooke, "Antisense Therapeutics," Biotechnology and Genetic Engineering Reviews 15:121-157 (1998)
 - * Crooke, "Progress in Antisense Technology: The End of the Beginning," Methods in Enzymology 313:3-45 (1999)
 - * Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of *in Vitro* Reaction Rates and Products," J. Mol. Biol. 256:31-49 (1996)
 - * deFazio et al., "Antisense Estrogen Receptor RNA Expression Increases Epidermal Growth Factor Receptor Gene Expression in Breast Cancer Cells," Cell Growth & Differentiation 8:903-911 (1997)
 - * Delihais et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," Nature Biotechnology 15:751-753 (1997)
 - * Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6:92-93 (1988)
 - * Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," Journal of Virology 66:1432-1441 (1992)
 - * Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," Nucleic Acids Research 18:6353-6359 (1990)
 - * Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides,"

Proc. Natl. Acad. Sci. USA 89:504-508 (1992)

- * Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," *Biopolymers* 48:39-55 (1998)
- * Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," Nature 365:566-568 (1993)
- 7. Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in Delivery Strategies for Antisense Oligonucleotide Therapeutics, edited by Akhtar, CRC Press, pp. 17-220 (1995)
- * Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990)
- * Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," *Cell Transplantation* 8:47-58 (1999)
- * Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," J. Am. Chem. Soc. 113:4000-4002 (1991)
- 8. Flanagan et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," *Nature Biotechnology*, Vol. 17, No. 1, pages 48-52 (Jan. 1999)
- * Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786 (1990)
- * Fox, "Targeting DNA with Triplexes," *Current Medicinal Chemistry* 7:17-37 (2000)
- * Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," Proc. Natl. Acad. Sci. USA 83:9373-9377 (1986)
- * Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," Nucleic Acids Research 21:2867-2872 (1993)
- * Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," *Neuroscience* 76:1153-1158 (1997)
- * Good et al., "Expression of small, therapeutic RNAs in human nuclei," Gene Therapy 4:45-54 (1997)
- * Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," Biochemistry 34:4068-4076 (1995)
- * Green et al., "Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A," Nature 320:134-139 (1986)
- 9. Green et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulations of Gene Expression in Human Disease," *J. Am. Coll. Surg.*, 93-105 (2000)
- * Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," Chemistry & Biology 2:761-770 (1995)
- * Groothuis et al., "The entry of antiviral and antiretroviral drugs into the central nervous

- system," *J. NeuroVirol* 3:387-400 (1997)
- * Guo and Collins, "Efficient *trans*-cleavage of a stem-loop RNA substrate by a ribozyme derived from *Neurospora* VS RNA," *EMBO J.* 14:368-376 (1995)
 - * Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," *Antisense & Nucleic Acid Drug Development* 9:25-31 (1999)
 - * Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," *Nucleic Acids Research* 18:299-304 (1990)
 - * Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," *RNA* 1:210-218 (1995)
 - * Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," *Nature* 334:585-591 (1988)
 - * Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," *Biochemistry* 34:15813-15828 (1995)
 - * Henningfeld et al., "Alteration of DNA Primary Structure by DNA Topoisomerase I. Isolation of the Covalent Topoisomerase I-DNA Binary Complex in Enzymatically Competent Form," *J. Am. Chem. Soc.* 118:11701-11714 (1996)
 - * Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," *Biochemistry* 29:10159-10171 (1990)
 - * Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," *Biochemistry* 29:10172-10180 (1990)
 - * Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," *Biochemistry* 33:3374-3385 (1994)
 - * Hertel et al., "Numbering System for the Hammerhead," *Nucleic Acids Research* 20:3252 (1992)
 - * Higson et al., "Synthesis and Structure of *S*-Nucleosidyl *S*-Aryl Disulfides and their Reaction with Phosphites," *Tetrahedron* 52:1027-1034 (1996)
 - 10. Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," *Current Opinion in Molecular Therapeutics* 1:336-343 (1999)
 - * Hostomsky et al., "Ch. 11 - Ribonucleases H," in *Nucleases*, edited by Linn et al., Cold Spring Harbor Laboratory Press, NY, pp. 341-376 (1993)
 - * Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H," *FEBS Letters* 215:327-330 (1987)
 - * Inoue et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl) ribonucleotides," *Nucleic Acids Research* 15:6131-6149 (1987)
 - * Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," *Chem. Pharm. Bull.*

43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)

11. Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," Biochemical and Biophysical Research Communication 214(2):403-409 (1995)
 - * Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)
 - * Jaeger et al., "Improved Predictions of Secondary Structures for RNA," Proc. Natl. Acad. Sci. USA 86:7706-7710 (1989)
 - * Jankowsky et al., "Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates," Nucleic Acids Research 25:2690-2693 (1997)
 - * Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," Tetrahedron Letters 34:301-304 (1993)
 - * Jeffries and Symons, "A Catalytic 13-mer Ribozyme," Nucleic Acids Research 17:1371-1377 (1989) (also referred to as Jefferies)
12. Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 18:207-319 (2000)
 - * Jiang et al., "Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected with Complementary DNAs for Estrogen Receptor," J. Natl. Cancer Inst. 84:580-591 (1992)
 - * Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)
 - * Jordan et al., "Endocrine Pharmacology of Antiestrogens as Antitumor Agents," Endocrine Reviews 11:578-610 (1990)
 - * Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," Genes & Development 7:130-138 (1993)
 - * Joyce et al., "Amplification, mutation and selection of catalytic RNA," Gene 82:83-87 (1989)
 - * Joyce, "Directed Molecular Evolution," Scientific American 267:90-97 (1992)
 - * Karpeisky et al., "2'-O-Methylthiomethyl Modifications In Hammerhead Ribozymes," Nucleosides & Nucleotides 16(7-9):955-958 (1997)
 - * Karpeisky et al., "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998)
 - * Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992)
 - * Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of *Tetrahymena*," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987)

- * Kim et al., "Inhibition of Transcription of the Human *c-myc* Protooncogene by Intermolecular Triplex," Biochemistry 37:2299-2304 (1998)
- * Klubmann et al., "Mirror-image RNA that binds D-adenosine," Nature Biotechnology 14:1112-1115 (1996)
- * Knitt et al., "pH Dependencies of the *Tetrahymena* Ribozyme Reveal an Unconventional Origin of an Apparent pK_a ," Biochemistry 35:1560-1570 (1996)
- 13. Koga et al., "Alternating α,β -Oligothymidylates with Alternating (3'→3')- and (5'→5') – Internucleotidic Phosphodiester Linkages as Models for Antisense Oligodeoxyribonucleotides," The Journal of Organic Chemistry, 56:3757-2759 (1991)
- * Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule", Nucleic Acids Research, 26(18):4116-4120 (1998)
- * Kumar and Ellington, "Artificial evolution and natural ribozymes," FASEB J. 9:1183-1195 (1995)
- * Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," Chemical Reviews 95:2601-2627 (1995)
- * Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)
- * Lehmann et al., "Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5'-hydroxyl protection," Nucleic Acids Research 17:2379-2390 (1989)
- * L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)
- * Li et al., "Application of the Michaelis-Arbusov Reaction to the Synthesis of Internucleoside 3'-S-Phosphorothiolate Linkages," J. Chem. Soc. Perkin Trans. I 15:2123-2129 (1994)
- * Li et al., "Synthesis of a Dinucleoside 3'-S-Phosphorothiolate Containing 2'-Deoxy-3'-Thioadenosine," Tetrahedron 48:2729-2738 (1992)
- * Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the *Tetrahymena* Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," Biochemistry 34:14394-14399 (1995)
- * Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
- * Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 22(12):2183-2196 (1994)
- * Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," J. Mol. Biol. 235:1206-1217 (1994)
- * Lisiewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993)
- * Liu et al., "3'-Thiouridylyl-(3'→5')-uridine," Tetrahedron Letters 37:925-928 (1996)

- * Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem. 270(42):24864-24870 (1995)
- * Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," Proc. Natl. Acad. Sci. USA 91:6977-6981 (1994)
- * Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," Biochemistry 32:1751-1758 (1993)
- * Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," Nucleic Acids Research 21:2585-2589 (1993)
- 14. Ma et al., "Synthetic oligonucleotides as therapeutics: the coming of age," *Biotechnology Annual Review*, 5:155-196 (2000)
- * Matulic-Adamic et al., "Synthesis and Incorporation of 2'-Amino Acid Conjugated Nucleotides Into Ribozymes," Biorganic & Medicinal Chemistry Letters 5:2721-2724 (1995)
- * Matulic-Adamic et al., "Synthesis and Incorporation of 5'-Amino- and 5'-Mercapto-5'-Deoxy-2'-O-Methyl Nucleosides Into Hammerhead Ribozymes," Nucleosides & Nucleotides 16:1933-1950 (1997)
- * McCarthy et al., "Enduring Consequences of Neonatal Treatment with Antisense Oligodeoxynucleotides to Estrogen Receptor Messenger Ribonucleic Acid on Sexual Differentiation of Rat Brain," Endocrinology 133:433-439 (1993)
- * McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" Nucleosides & Nucleotides 10:287-290 (1991)
- * McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
- * McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," RNA 2:395-403 (1996)
- * Mengel and Griesser, "Nucleophilic Displacement Reactions with Thiobenzoate. New Syntheses of Deoxy-Thioadenosine Derivatives Starting from Adenosine," Tetrahedron Letters 13:1177-1180 (1977)
- * Michel and Westhof, "Slippery substrates," Nat. Struct. Biol. 1:5-7 (1994)
- * Michel et al., "Structure and Activities of Group II Introns," Annu. Rev. Biochem. 64:435-461 (1995)
- * Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," Biochemistry 34:2965-2977 (1995)
- * Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," Proc. Natl. Acad. Sci. USA 93:6780-6785 (1996)
- * Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as

Antisense Inhibitors of Gene Expression," J. Biol. Chem. 268:14514-14522 (1993)

- * Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," Science 256:992-996 (1992)
- * Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," Critical Reviews in Oncogenesis 7:151-190 (1996)
- * Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," Biochemistry 33:1271-1277 (1994)
- * Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," Ann. Rev. Biochem. 44:273-293 (1975)
- * Noonberg et al., *In vivo* generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994)
- * Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," Nucleic Acids Symp. Ser. 27:15-16 (1992)
- * Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," Proc. Natl. Acad. Sci. USA 89:10802-10806 (1992)
- * Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," Biochimica et Biophysica Acta 1238:86-90 (1995)
- * Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," Biochemistry 30:9914-9921 (1991)
- * Orgel, "Selection *in vitro*," Proc. R. Soc. London B. 205:435-442 (1979)
- * Pace and Smith, "Ribonuclease P: Function and Variation," J. Biol. Chem. 265:3587-3590 (1990)
- * Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," Proc. Natl. Acad. Sci. USA 92:12510-12514 (1995)
- * Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," Science 268:567-569 (1995)
- * Pardridge et al., "Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier *in vivo*," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995)
- * Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault)
- * Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," Nature 350:434-436 (1991)
- * Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," Biochemistry 31:16-21 (1992)

- * Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991)
- * Pink and Jordan, "Models of Estrogen Receptor Regulation by Estrogens and Antiestrogens in Breast Cancer Cell Lines," Cancer Research 56:2321-2330 (1996)
- * Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," Pharmacol Ther. 78:55-113 (1998)
- * Potts et al., "Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β 3," Proc. Natl. Acad. Sci. USA 88:1516-1520 (1991)
- * Praseuth et al., "Triple helix formation and the antigen for sequence-specific control of gene expression," Biochimica et Biophysica Acta 1489:181-206 (1999)
- * Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," Nucleic Acids Research 21:4253-4258 (1993)
- * Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," Biochemistry 33:2716-2725 (1994)
- * Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," J. Am. Chem. Soc. 113:5109-5111 (1991)
- * Robertson et al., "Purification and Properties of a Specific *Escherichia coli* Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," J. Biol. Chem. 247:5243-5251 (1972)
- * Rosemeyer and Seela, "72. 1(2'-Deoxy- β -D-xylofuranosyl)thymine Building Blocks for Solid-Phase Synthesis and Properties of Oligo(2-Deoxyxynucleotides)," Helvetica Chimica Acta 74:748-760 (1991)
- * Russell et al., "Reactions of 2-Acyloxyisobutryl Halides with Nucleosides. II. Reactions of Adenosine," J. Am. Chem. Soc. 95:4025-4030 (1973)
- * Ryan et al., "Intramolecular Displacement by Neighboring O-Thionobenzoate. Synthesis of 3'-Thioadenosine," J. Org. Chem. 33:1783-1789 (1968)
- * Santagati et al., "Oligonucleotide Squelching Reveals the Mechanism of Estrogen Receptor Autologous Down-Regulation," Molecular Endocrinology 11:938-949 (1997)
- * Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997)
- * Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," J. Am. Chem. Soc. 122:2433-2439 (2000)
- * Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" Science 247:1222-1225 (1990)
- * Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," Proc. Natl. Acad. Sci. USA 88:10591-10595 (1991)

- * Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," Nucl Acids Res. 18:5433-5441 (1990)
- * Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," *The Journal of Biological Chemistry* 274:21783-21789 (1999)
- * Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996)
- 15. Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.* 23:941-949 (1999)
- * Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," Cell 81:991-1002 (1995)
- * Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," Nucleic Acids Research 15:3113-3129 (1987)
- * Seela et al., "122. Xylose-DNA Containing the Four Natural Bases," Helvetica Chimica Acta 79:1451-1461 (1996)
- * Seela et al., "83. 1(2'-Deoxy- β -D-xylofuranosyl)cytosine: Base Pairing of Oligonucleotides with a Configurationally Altered Sugar-Phosphate Backbone," Helvetica Chimica Acta 77:883-896 (1994)
- * Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," Nucleic Acids Research 19:4247-4251 (1991)
- * Shibahara et al., "Site-directed cleavage of RNA," Nucleic Acids Research 15:4403-4415 (1987)
- * Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," *Methods in Enzymology* 313:522-533 (1999)
- * Sontheimer et al., "Metal ion catalysis during splicing of premessenger RNA," Nature 388:801-805 (1997) (volume no. mistakenly referred to as 308)
- * Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" Science 261:1004-1288 (1993)
- * Stein et al., "A Specificity Comparison of Four Antisense types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," *Antisense N.A. Drug Dev.* 7:151 (1997)
- * Strobel et al., "Exocyclic Amine of the Conserved G·U Pair at the Cleavage Site of the *Tetrahymena* Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," Biochemistry 35:1201-1211 (1996)
- * Strobel et al., "Minor Groove Recognition of the Conserved G·U Pair at the *Tetrahymena* Ribozyme Reaction Site," Science 267:675-679 (1995)
- * Strobel et al., "The 2,6-Diaminopurine Riboside-5-Methylisocytidine Wobble Base Pair: An Isoenergetic Substitution for the Study of G·U Pairs in RNA," Biochemistry 33:13824-13835 (1994)

- * Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," Nature 371:619-622 (1994)
- * Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," Science 262:1566-1569 (1993)
- * Sun et al., "Synthesis of 3'-thioribonucleosides and their incorporation into oligoribonucleotides via phosphoramidite chemistry," RNA 3:1352-1363 (1997)
- * Szostak, "In Vitro Genes," TIBS 17:89-93 (1993)
- * Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both *in vitro* in place of run-off and (G)-free transcriptions and *in vivo* as multi-sequences transcription vectors," Nucleic Acids Research 19:5125-5130 (1991)
- * Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," RNA 3:914-925 (1997)
- * Tazawa et al., "L-Adenylyl-(3'-5')-L-adenosine and L-Adenylyl-(2'-5')-L-adenosine," Biochemistry 9:3499-3514 (1970)
- * Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," Nucleic Acids Research 23:2259-2268 (1995)
- * Tidd et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues," Anti-Cancer Drug Design 3:117-127 (1988)
- * Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
- * Turner et al., "Improved Parameters for Prediction of RNA Structure," Cold Spring Harbor Symposia on Quantitative Biology Volume LII, pp. 123-133 (1987)
- * Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," J. Am. Chem. Soc. 109:3783-3785 (1987)
- * Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," Proc. Natl. Acad. Sci. USA 96:7053-7058 (1999)
- * Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," FEBS Letters 421:280-284 (1998)
- * Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature 328:596-600 (1987) (this is listed as Nature 327 in the various specifications, but it is actually 328)
- * Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemical Reviews 90:544-584 (1990)
- * Usman and Cedergren, "Exploiting the chemical synthesis of RNA," TIBS 17:334-339 (1992)
- * Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," Annual Reports in Medicinal Chemistry 30:285-294 (1995)

- * Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an *Escherichia coli* Formylmethionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
- * Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Symposium Series 31:163-164 (1994)
- * Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology 1:527-533(1996)
- * Usman et al., WO 95/06731 published March 9, 1995, PCT/US94/09342 filed August 19, 1994 for "Non-Nucleotide Containing Enzymatic Nucleic Acid"
- * Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by *in Vitro* Selection," Biochemistry 36:6495-6501 (1997)
- * Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic Acids Research 21:3249-3255 (1993)
- * Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem. 67:99-134 (1998)
- * Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA Containing 3'-Thiothymidine," Biochemistry 31:3012-3018 (1992)
- * Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome," Chemistry & Biology, 6(4):237-250 (1999)
- * Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
- * Weinstein et al., "Synthesis and Characterization of an RNA Dinucleotide Containing a 3'-S-Phosphorothiolate Linkage," J. Am. Chem. Soc. 118:10341-10350 (1996)
- * Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," Nucleic Acids Research 23:2092-2096 (1995)
- * Williard et al., "Paradoxical production of target protein using antisense RNA expression vectors," Gene 149:21-24 (1994)
- * Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995)
- * Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in Molecular Biology 74:59-69 (1997)
- * Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," Biopharm, November 1994.
- * Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)


- * Yuan et al., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci. USA 89:8006-8010 (1992)
- 16. Zaia et al., "Status of Ribozyme and Antisense-Based Developmental Approaches for Anti-HIV-1 Therapy," Annals of the New York Acad of Sci. 660:95-106 (1992)
- * Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the *Tetrahymena* ribozyme," Nucleic Acids Research 24:854-858 (1996)
- * Zaug et al., "The *Tetrahymena* Ribozyme Acts Like an RNA Restriction Endonuclease," Nature 324:429-433 (1986)
- * Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
- * Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," Cell 83:529-538 (1995)

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: MARCH 23, 2004

By: _____


Christopher P. Singer
Reg. No. 48,701

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	09/103,636	06/23/98	Thompson et al.			
	*	09/886,316	05/25/01	Thompson et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/101,074	09/21/98	Hartmann, et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,987,071	01/22/91	Cech et al.			
	*	5,013,830	05/07/91	Ohtsuka et al.			
	*	5,144,019	09/01/92	Rossi et al.			
	*	5,264,423	11/23/93	Cohen et al.			
	*	5,272,065	12/21/93	Inouye et al.			
	*	5,276,019	01/04/94	Cohen et al.			
	*	5,286,717	02/15/94	Cohen et al.			
	*	5,334,711	08/02/94	Sproat et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	5,491,133	02/13/96	Walder et al.			
	*	5,496,698	03/05/96	Draper et al.			
	*	5,525,468	06/11/96	McSwiggen			
	*	5,576,208	11/19/96	Monia et al.			
	*	5,587,362	12/24/96	Chu et al.			
	*	5,623,065	04/22/97	Cook et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,625,047	04/29/97	Been et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,652,094	07/29/97	Usman et al.			
	*	5,652,355	07/29/97	Metelev et al.			
	*	5,652,356	07/29/97	Agrawal			
	*	5,678,731	10/21/97	Okamura et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,919,619	07/06/99	Tullis			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/07/99	Matulic-Adamic et al.			
	*	6,001,311	12/12/00	Brennan			
	*	6,001,653	12/04/99	Crooke et al.			
	*	6,127,173	10/03/00	Eckstein et al.			
	*	6,159,714	12/14/99	Usman et al.			
	*	6,365,730	02/02/02	Jennings et al.			
	*	6,420,546	07/16/02	Seliger et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	0 360 257 A2	03/28/90	EPO (Hampel et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	04/30/92	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23569	11/25/93	WO (Draper et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	94/02595	02/03/94	WO (Sullivan et al.)				
	1.	95/06731	03/09/95	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz)				
	*	96/10390	04/11/96	WO (Ansell et al.)				
	*	96/10391	04/11/96	WO (Choi et al.)				
	*	96/10392	04/11/96	WO (Holland et al.)				
	*	96/17086	06/06/96	WO (Joyce et al.)				
	*	96/18736	06/20/96	WO (Beigelman et al.)				
	*	96/19577	06/27/96	WO (Collins)				
	*	97/26270	07/24/97	WO (Wincott et al.)				
	*	98/13526	04/02/98	WO (Woolf)				
	*	98/58058	12/23/98	WO (Ludwig et al.)				
	*	99/04819	02/04/99	WO (Klimuk et al.)				
	*	99/05094	07/22/98	WO (Beigelman et al.)				
	*	99/16871	04/08/99	WO (Eckstein et al.)				
	*	99/54459	10/28/99	WO (Thompson et al.)				
	*	99/55857	04/28/99	WO (Beigelman et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group:

	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <i>Science</i> 271:1410-1413 (1996)
	*	Agrawal et al., "Site-specific excision from RNA by Rnase H and mixed-phosphate-backbone oligodeoxynucleotides," <i>Proc. Nat. Acad. Sci. USA</i> 87:1401-1405 (1990)
	2.	Agrawal et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81 (2000)
	*	Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," <i>Trends in Cell Biology</i> 2:139-144 (1992)
	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)
	*	Altmann et al., "Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals," <i>Chimia</i> 50:168-176 (1996)
	*	Ashley, "Modeling, Synthesis, and Hybridization Properties of (L)-Ribonucleic Acid," <i>J. Am. Chem. Soc.</i> 114:9731-9736 (1992)
	*	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <i>Biochemistry</i> 34:6504-6512 (1995)
	*	Bartel and Szostak, "Isolation of New Ribozymes From a Large Pool of Random Sequences," <i>Science</i> 261:1411-1418 (1993)
	*	Beaucage et al., "The functionalization of oligonucleotides via phosphoramidite derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	*	Beaudry et al., "Directed Evolution of an RNA Enzyme," <i>Science</i> 257:635-641 (1992)
	*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>J. Biol. Chem.</i> 270:25702-25708 (1995)
	*	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
	*	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid-Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)
	3.	Bennett et al., "Pharmacology of Antisense Therapeutic Agents," <i>Methods in Molecular Medicine</i> , 13-46 (1996)
	*	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <i>EBMO J.</i> 12:2567-2574 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <i>Genes & Development</i> 6:129-134 (1992)
	*	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <i>Biochemistry</i> 35:648-658 (1996)
	*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	*	Borras et al., "Estradiol-induced Down-regulation of Estrogen Receptor. Effect of Various Modulators of Protein Synthesis and Expression," <i>J. Steroid Biochem. Molec. Biol.</i> 48:325-336 (1994)
	*	Borras et al., "Estrogenic and Antiestrogenic Regulation of the Half-life of Covalently Labeled Estrogen Receptor in MCF-7 Breast Cancer Cells," <i>J. Steroid Biochem. Molec. Biol.</i> 57:203-213 (1996)
	4.	Branch, "A good antisense molecule is hard to find," <i>TIBS</i> 23:45-50 (1998)
	*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
	*	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
	*	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
	*	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
	*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no mistakenly listed as 6)
	*	Burke et al., "Structural Analysis and Modifications of the Hairpin Ribozyme," <i>Nucleic Acids and Molecular Biology</i> , edited by Eckstein and Lilley, Springer-Verlag Berlin Heidelberg, 10:129-143 (1996)
	*	Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)
	*	Cao and Matteucci, "Preparation, Characterization and Binding Properties of an Oligodeoxynucleotide Containing the 3'-Ribothioformacetal Phosphate Analog," <i>Bioorganic & Medicinal Chemistry Letters</i>

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		4:807-810 (1994)
	*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
	*	Cech et al., "Representation of the secondary and tertiary structure of group I introns," <u>structural biology</u> 1:273-280 (1994)
	*	Cech, "Ribozymes and Their Medical Implications," <u>JAMA</u> 260:3030-3034 (1988)
	*	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <u>Nucleic Acids Research</u> 23(20):4092-4096 (1995)
	*	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
	*	Chowrira et al., " <i>In Vitro</i> and <i>in Vivo</i> Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
	*	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <u>Nature</u> 354:320-322 (1991)
	*	Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," <u>J. Med. Chem.</u> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
	*	Christoffersen, "Translating genomics information into therapeutics: A Key Role for Oligonucleotides," <u>Nature Biotechnology</u> 15:483-484 (1997) (Christofferson)
	*	Christofferson et al., "Application of computational technologies to ribozyme biotechnology products," <u>Journal of Molecular Structure (Theochem)</u> 311:273-284 (1994) (Christofferson)
	*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)
	5.	Cook et al., "Ch. 9 - Medicinal Chemistry Strategies for Antisense Research," <u>Antisense Research and Applications</u> , CRC Press, Inc., pp. 140-181 (1993)
	*	Cook et al., "The Use of Antisense Oligonucleotides to Establish Autocrine Angiotensin Growth Effects in Human Nueroblastoma and Mesangial Cells," <u>Antisense Research and Development</u> 2:199-210 (1992)
	*	Cosstick et al, "Synthesis and properties of dithymidine phosphate analogues containing 3'-thiothymidine," <u>Nucleic Acids. Research</u> 18:829-835 (1990)
	*	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <u>Trends In Genetics</u> 12:510-515 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	Crooke et al., "Kinetic characteristics of <i>Escherichia coli</i> Rnase H1: Cleavage of various antisense oligonucleotide-RNA duplexes," <i>Biochem. J.</i> 312:599-608 (1995)
	6.	Crooke et al., "Progress in the development and patenting of antisense drug discovery technology," <i>Exp. Opin. Ther. Patents</i> , 6, 855 (1996)
	*	Crooke, "Progress in Antisense Therapeutics," <i>Medicinal Research Reviews</i> 16:319-344 (1996)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," <i>Methods in Enzymology</i> 313:3-45 (1999)
	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <i>J. Mol. Biol.</i> 256:31-49 (1996)
	*	deFazio et al., "Antisense Estrogen Receptor RNA Expression Increases Epidermal Growth Factor Receptor Gene Expression in Breast Cancer Cells," <i>Cell Growth & Differentiation</i> 8:903-911 (1997)
	*	Delibas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <i>Nature Biotechnology</i> 15:751-753 (1997)
	*	Dreyfus, "Restriction Ribozymes?" <i>Einstein Quarterly Journal of Biology and Medicine</i> 6:92-93 (1988)
	*	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990)
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992)
	*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> 365:566-568 (1993)
	7.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	*	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
	*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)
	8.	Flanagan et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," <u>Nature Biotechnology</u> , Vol. 17, No. 1, pages 48-52 (Jan. 1999)
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," <u>Current Medicinal Chemistry</u> 7:17-37 (2000)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986)
	*	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
	*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <u>Neuroscience</u> 76:1153-1158 (1997)
	*	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
	*	Green et al., "Human oestrogen receptor cDNA: sequence, expression and homology to <i>v-erb-A</i> ," <u>Nature</u> 320:134-139 (1986)
	9.	Green et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulations of Gene Expression in Human Disease," <u>J. Am. Coll. Surg.</u> , 93-105 (2000)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <u>Chemistry & Biology</u> 2:761-770 (1995)
	*	Groothuis et al., "The entry of antiviral and antiretroviral drugs into the central nervous system," <u>J. NeuroVirol</u> 3:387-400 (1997)
	*	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <u>EMBO J.</u> 14:368-376 (1995)
	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <u>Antisense & Nucleic Acid Drug Development</u> 9:25-31 (1999)
	*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		Substrate RNA," <u>Nucleic Acids Research</u> 18:299-304 (1990)
	*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <u>RNA</u> 1:210-218 (1995)
	*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <u>Nature</u> 334:585-591 (1988)
	*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <u>Biochemistry</u> 34:15813-15828 (1995)
	*	Henningfeld et al., "Alteration of DNA Primary Structure by DNA Topoisomerase I. Isolation of the Covalent Topoisomerase I-DNA Binary Complex in Enzymatically Competent Form," <u>J. Am. Chem. Soc.</u> 118:11701-11714 (1996)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <u>Biochemistry</u> 29:10159-10171 (1990)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <u>Biochemistry</u> 29:10172-10180 (1990)
	*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <u>Biochemistry</u> 33:3374-3385 (1994)
	*	Hertel et al., "Numbering System for the Hammerhead," <u>Nucleic Acids Research</u> 20:3252 (1992)
	*	Higson et al., "Synthesis and Structure of S-Nucleosidyl S-Aryl Disulfides and their Reaction with Phosphites," <u>Tetrahedron</u> 52:1027-1034 (1996)
	10.	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," <u>Current Opinion in Molecular Therapeutics</u> 1:336-343 (1999)
	*	Hostomsky et al., "Ch. 11 - Ribonucleases H," in <u>Nucleases</u> , edited by Linn et al., Cold Spring Harbor Laboratory Press, NY, pp. 341-376 (1993)
	*	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H," <u>FEBS Letters</u> 215:327-330 (1987)
	*	Inoue et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl) ribonucleotides," <u>Nucleic Acids Research</u> 15:6131-6149 (1987)
	*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

11.	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)
*	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)
*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," <u>Proc. Natl. Acad. Sci. USA</u> 86:7706-7710 (1989)
*	Jankowsky et al., "Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates," <u>Nucleic Acids Research</u> 25:2690-2693 (1997)
*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993)
*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
12.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <u>Stem Cells</u> , 18:307-319 (2000)
*	Jiang et al., "Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected with Complementary DNAs for Estrogen Receptor," <u>J. Natl. Cancer Inst.</u> 84:580-591 (1992)
*	Joliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
*	Jordan et al., "Endocrine Pharmacology of Antiestrogens as Antitumor Agents," <u>Endocrine Reviews</u> 11:578-610 (1990)
*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes & Development</u> 7:130-138 (1993)
*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
*	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
*	Karpeisky et al, "2'-O-Methylthiomethyl Modifications In Hammerhead Ribozymes," <u>Nucleosides & Nucleotides</u> 16(7-9):955-958 (1997)
*	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
*	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		<i>Tetrahymena</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 84:8788-8792 (1987)
	*	Kim et al., "Inhibition of Transcription of the Human <i>c-myc</i> Protooncogene by Intermolecular Triplex," <u>Biochemistry</u> 37:2299-2304 (1998)
	*	Klubmann et al., "Mirror-image RNA that binds D-adenosine," <u>Nature Biotechnology</u> 14:1112-1115 (1996)
	*	Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK_a ," <u>Biochemistry</u> 35:1560-1570 (1996)
	13.	Koga et al., "Alternating α,β -Oligothymidylates with Alternating (3'→3')- and (5'→5') – Internucleotidic Phosphodiester Linkages as Models for Antisense Oligodeoxyribonucleotides," <u>The Journal of Organic Chemistry</u> , 56:3757-2759 (1991)
	*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule", <u>Nucleic Acids Research</u> , 26(18):4116-4120 (1998).
	*	Kumar and Ellington, "Artificial evolution and natural ribozymes," <u>FASEB J.</u> 9:1183-1195 (1995)
	*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <u>Chemical Reviews</u> 95:2601-2627 (1995)
	*	Lasic and Papahadjopoulos, "Liposomes Revisited," <u>Science</u> 267:1275-1276 (1995)
	*	Lehmann et al., "Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5'-hydroxyl protection," <u>Nucleic Acids Research</u> 17:2379-2390 (1989)
	*	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <u>EMBO J.</u> 11:4411-4418 (1992)
	*	Li et al., "Application of the Michaelis-Arbusov Reaction to the Synthesis of Internucleoside 3'-S-Phosphorothiolate Linkages," <u>J. Chem. Soc. Perkin Trans. I</u> 15:2123-2129 (1994)
	*	Li et al., "Synthesis of a Dinucleoside 3'-S-Phosphorothiolate Containing 2'-Deoxy-3'-Thioadenosine," <u>Tetrahedron</u> 48:2729-2738 (1992)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <u>Biochemistry</u> 34:14394-14399 (1995)
	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <u>Methods Enzymol.</u> 217:47-66 (1993)
	*	Limbach et al., "Summary: the modified nucleosides of RNA," <u>Nucleic Acids Research</u> 22(12):2183-2196 (1994)
	*	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <u>J. Mol.</u>

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		Biol. 235:1206-1217 (1994)
	*	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	*	Liu et al., "3'-Thiouridylyl-(3'→5')-uridine," <i>Tetrahedron Letters</i> 37:925-928 (1996)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	14.	Ma et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <i>Biotechnology Annual Review</i> , 5:155-196 (2000)
	*	Matulic-Adamic et al., "Synthesis and Incorporation of 2'-Amino Acid Conjugated Nucleotides Into Ribozymes," <i>Biorganic & Medicinal Chemistry Letters</i> 5:2721-2724 (1995)
	*	Matulic-Adamic et al., "Synthesis and Incorporation of 5'-Amino- and 5'-Mercapto-5'-Deoxy-2'-O-Methyl Nucleosides Into Hammerhead Ribozymes," <i>Nucleosides & Nucleotides</i> 16:1933-1950 (1997)
	*	McCarthy et al., "Enduring Consequences of Neonatal Treatment with Antisense Oligodeoxynucleotides to Estrogen Receptor Messenger Ribonucleic Acid on Sexual Differentiation of Rat Brain," <i>Endocrinology</i> 133:433-439 (1993)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991)
	*	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)
	*	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <i>RNA</i> 2:395-403 (1996)
	*	Mengel and Griesser, "Nucleophilic Displacement Reactions with Thiobenzoate. New Syntheses of Deoxy-Thioadenosine Derivatives Starting from Adenosine," <i>Tetrahedron Letters</i> 13:1177-1180 (1977)
	*	Michel and Westhof, "Slippery substrates," <i>Nat. Struct. Biol.</i> 1:5-7 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461 (1995)
	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)
	*	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," <u>Proc. Natl. Acad. Sci. USA</u> 93:6780-6785 (1996)
	*	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <u>J. Biol. Chem.</u> 268:14514-14522 (1993)
	*	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
	*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <u>Critical Reviews in Oncogenesis</u> 7:151-190 (1996)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)
	*	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
	*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
	*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
	*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta</u> 1238:86-90 (1995)
	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry</u> 30:9914-9921 (1991)
	*	Orgel, "Selection <i>in vitro</i> ," <u>Proc. R. Soc. London B</u> , 205:435-442 (1979)
	*	Pace and Smith, "Ribonuclease P: Function and Variation," <u>J. Biol. Chem.</u> 265:3587-3590 (1990)
	*	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," <u>Proc. Natl. Acad. Sci. USA</u> 92:12510-12514 (1995)
	*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		Angiogenesis," <i>Science</i> 268:567-569 (1995)
	*	Pardridge et al., " Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
	*	Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis delta virus RNA," <i>Nature</i> 350:434-436 (1991)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <i>Biochemistry</i> 31:16-21 (1992)
	*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	*	Pink and Jordan, "Models of Estrogen Receptor Regulation by Estrogens and Antiestrogens in Breast Cancer Cell Lines," <i>Cancer Research</i> 56:2321-2330 (1996)
	*	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> J78:55-113 (1998)
	*	Potts et al., "Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β 3," <i>Proc. Natl. Acad. Sci. USA</i> 88:1516-1520 (1991)
	*	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)
	*	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:4253-4258 (1993)
	*	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <i>Biochemistry</i> 33:2716-2725 (1994)
	*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)
	*	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <i>J. Biol. Chem.</i> 247:5243-5251 (1972)
	*	Rosemeyer and Seela, "72. 1(2'-Deoxy- β -D-xylofuranosyl)thymine Building Blocks for Solid-Phase Synthesis and Properties of Oligo(2-Deoxyxylonucleotides)," <i>Helvetica Chimica Acta</i> 74:748-760 (1991)
	*	Russell et al., "Reactions of 2-Acyloxyisobutyryl Halides with Nucleosides. II. Reactions of

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

		Adenosine," <u>J. Am. Chem. Soc.</u> 95:4025-4030 (1973)
	*	Ryan et al., "Intramolecular Displacement by Neighboring O-Thionobenzoate. Synthesis of 3'-Thioadenosine," <u>J. Org. Chem.</u> 33:1783-1789 (1968)
	*	Santagati et al., "Oligonucleotide Squelching Reveals the Mechanism of Estrogen Receptor Autologous Down-Regulation," <u>Molecular Endocrinology</u> 11:938-949 (1997)
	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
	*	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <u>J. Am. Chem. Soc.</u> 122:2433-2439 (2000)
	*	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	*	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
	*	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <u>The Journal of Biological Chemistry</u> 274:21783-21789 (1999)
	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996)
	15.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <u>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</u> 23:941-949 (1999)
	*	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <u>Cell</u> 81:991-1002 (1995)
	*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)
	*	Seela et al., "122. Xylose-DNA Containing the Four Natural Bases," <u>Helvetica Chimica Acta</u> 79:1451-1461 (1996)
	*	Seela et al., "83. 1(2'-Deoxy- β -D-xylofuranosyl)cytosine: Base Pairing of Oligonucleotides with a Configurationally Altered Sugar-Phosphate Backbone," <u>Helvetica Chimica Acta</u> 77:883-896 (1994)
	*	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
	*	Shibahara et al., "Site-directed cleavage of RNA," <u>Nucleic Acids Research</u> 15:4403-4415 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

*	Silverman et al., "Selective RNA Cleavage by Isolated Rnase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
*	Sontheimer et al., "Metal ion catalysis during splicing of premessenger RNA," <i>Nature</i> 388:801-805 (1997) (volume no. mistakenly referred to as 308)
*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
*	Stein et al., "A Specificity Comparison of Four Antisense types: Morpholino, 2'-O'Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense N.A. Drug Dev.</i> 7:151 (1997)
*	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <i>Biochemistry</i> 35:1201-1211 (1996)
*	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Reaction Site," <i>Science</i> 267:675-679 (1995)
*	Strobel et al., "The 2,6-Diaminopurine Riboside-5-Methylisocytidine Wobble Base Pair: An Isoenergetic Substitution for the Study of G-U Pairs in RNA," <i>Biochemistry</i> 33:13824-13835 (1994)
*	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:619-622 (1994)
*	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
*	Sun et al., "Synthesis of 3'-thioribonucleosides and their incorporation into oligoribonucleotides via phosphoramidite chemistry," <i>RNA</i> 3:1352-1363 (1997)
*	Szostak, "In Vitro Genes," <i>TIBS</i> 17:89-93 (1993)
*	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <i>RNA</i> 3:914-925 (1997)
*	Tazawa et al., "L-Adenylyl-(3'-5')-L-adenosine and L-Adenylyl-(2'-5')-L-adenosine," <i>Biochemistry</i> 9:3499-3514 (1970)
*	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
*	Tidd et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	(Use several sheets if necessary)	00-873-I (500.011)	10/715,285
		Applicant: Thompson et al.	
		Filing Date:	Group:
		November 17, 2003	

		methylphosphonate oligonucleotide analogues," <u>Anti-Cancer Drug Design</u> 3:117-127 (1988)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <u>Proc. Natl. Acad. Sci. USA</u> 90:1300-1304 (1993)
	*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</u> , pp. 123-133 (1987)
	*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
	*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999)
	*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," <u>Nature</u> 328:596-600 (1987) (this is listed as Nature 327 in the various specifications, but it is actually 328)
	*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> 90:544-584 (1990)
	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
	*	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995)
	*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
	*	Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533(1996)
	*	Usman et al., WO 95/06731 published March 9, 1995, PCT/US94/09342 filed August 19, 1994 for "Non-Nucleotide Containing Enzymatic Nucleic Acid"
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
	*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u>

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
	Applicant: Thompson et al.	
	Filing Date: November 17, 2003	Group:

		21:3249-3255 (1993)
	*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
	*	Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA Containing 3'-Thiothymidine," <i>Biochemistry</i> 31:3012-3018 (1992)
	*	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome," <i>Chemistry & Biology</i> , 6(4):237-250 (1999)
	*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <i>Journal of Virology</i> 65:5531-5534 (1994)
	*	Weinstein et al., "Synthesis and Characterization of an RNA Dinucleotide Containing a 3'-S-Phosphorothiolate Linkage," <i>J. Am. Chem. Soc.</i> 118:10341-10350 (1996)
	*	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <i>Nucleic Acids Research</i> 23:2092-2096 (1995)
	*	Williard et al., "Paradoxical production of target protein using antisense RNA expression vectors," <i>Gene</i> 149:21-24 (1994)
	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <i>Nucleic Acids Research</i> 23(14):2677-2684 (1995)
	*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <i>Methods in Molecular Biology</i> 74:59-69 (1997)
	*	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," <i>Biopharm</i> , November 1994.
	*	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344 (1993)
	*	Yuan et al., "Targeted cleavage of mRNA by human RNase P," <i>Proc. Natl. Acad. Sci. USA</i> 89:8006-8010 (1992)
	16.	Zaia et al., "Status of Ribozyme and Antisense-Based Developmental Approaches for Anti-HIV-1 Therapy," <i>Annals of the New York Acad of Sci.</i> 660:95-106 (1992)
	*	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <i>Nucleic Acids Research</i> 24:854-858 (1996)
	*	Zaug et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease," <i>Nature</i> 324:429-433 (1986)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-873-I
(500.011)

Serial No.

10/715,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant: Thompson et al.

Filing Date:

November 17, 2003

Group:

	*	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <u>Cell</u> 83:529-538 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.